OA: (Review) Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials | Wu | Oncotarget Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Monday, October 31, 2016

OA: (Review) Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials | Wu | Oncotarget



open access
Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials

 Literature search and inclusion criteria
The literature search focused on randomized controlled trials published from database inception to May 2016. Studies comparing bevacizumab plus chemotherapy with chemotherapy alone were eligible for inclusion. We searched the PubMed, EMBASE, Web of Science and Central (Cochrane clinical trials database) databases, and we also searched clinicaltrial.gov. We used the search terms “bevacizumab”, “Avastin”, “chemotherapy”, and “ovarian cancer” in various combinations. In addition, only phase III randomized trials were restricted in the search strategy. The language of an article published was not restricted.
 CONCLUSIONS
This updated meta-analysis indicates that bevacizumab combined with chemotherapy significantly improved PFS and OS in both patients with high-risk of progression and patients with recurrent OC, with an increased incidence of common adverse events. However, no statistically significant survival benefit was identified in the front-line settings. ORR is improved in overall population by the addition of bevacizumab.


0 comments :

Post a Comment

Your comments?